Docstoc

Synergy Pharmaceuticals’ Plecanatide Phase 2b Trial in IBS-C Reaches Enrollment Halfway Mark

Document Sample
Synergy Pharmaceuticals’ Plecanatide Phase 2b Trial in IBS-C Reaches Enrollment Halfway Mark Powered By Docstoc
					
				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:0
posted:7/17/2013
language:Japanese
pages:3
Description: NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) today announced that it has reached the halfway mark for total enrollment in its ongoing plecanatide Phase 2b clinical trial in IBS-C patients.
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.